Scailyte and Geninus announce a strategic partnership

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cell genomics provider Geninus, today announce a strategic partnership to develop a patient stratification and predictive platform for Non-Small Cell Lung Cancer (NSCLC).

The companies join their unique expertise in data generation and analysis: Geninus brings a variety of cutting-edge genomic analysis technologies and experienced global R&D specialists, and Scailyte leverages a best-in-class single-cell data analysis platform, ScaiVision, to identify and validate disease-specific molecular biomarkers. 

Through the joint venture, Geninus will lead the recruitment of NSCLC patients’ undergoing immune-checkpoint inhibitor (ICI) therapy and the processing of samples at a single-cell precision level, while Scailyte will drive the molecular biomarker discovery studies together with clinical key opinion leaders in the disease area. Following biomarker discovery, Geninus will focus on the prototyping, development and clinical validation of the prognostic assay.

The benefits of these joint efforts are copious: patients suffering from NSCLC will be stratified based on a ICI response-prediction assay, and the clinicians will have tools for an informed therapeutic decision, thereby ensuring a high response rate of patients ultimately selected for ICI. Moreover, new biological and therapeutic approaches could be explored on the basis of molecular markers that define response to ICI.